DE3886237T2 - Reinigung von LFA-3. - Google Patents

Reinigung von LFA-3.

Info

Publication number
DE3886237T2
DE3886237T2 DE88301709T DE3886237T DE3886237T2 DE 3886237 T2 DE3886237 T2 DE 3886237T2 DE 88301709 T DE88301709 T DE 88301709T DE 3886237 T DE3886237 T DE 3886237T DE 3886237 T2 DE3886237 T2 DE 3886237T2
Authority
DE
Germany
Prior art keywords
lfa
purification
quantitating
purifying
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88301709T
Other languages
English (en)
Other versions
DE3886237D1 (de
Inventor
Michael Dustin
Timothy Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of DE3886237D1 publication Critical patent/DE3886237D1/de
Application granted granted Critical
Publication of DE3886237T2 publication Critical patent/DE3886237T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE88301709T 1987-02-26 1988-02-26 Reinigung von LFA-3. Expired - Fee Related DE3886237T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1901087A 1987-02-26 1987-02-26

Publications (2)

Publication Number Publication Date
DE3886237D1 DE3886237D1 (de) 1994-01-27
DE3886237T2 true DE3886237T2 (de) 1994-05-05

Family

ID=21790939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE88301709T Expired - Fee Related DE3886237T2 (de) 1987-02-26 1988-02-26 Reinigung von LFA-3.

Country Status (6)

Country Link
EP (1) EP0280578B1 (de)
JP (1) JPS63276494A (de)
AT (1) ATE98649T1 (de)
CA (1) CA1326940C (de)
DE (1) DE3886237T2 (de)
ES (1) ES2061638T3 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ATE186552T1 (de) 1988-09-01 1999-11-15 Bayer Ag Menschliches rhinovirusrezeptorprotein, das die virusinfektionsanfälligkeit hemmt
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
JPH02262599A (ja) * 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
WO1992016563A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ATE210454T1 (de) * 1991-10-07 2001-12-15 Biogen Inc Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins
CA2454618C (en) 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities

Also Published As

Publication number Publication date
CA1326940C (en) 1994-02-08
EP0280578A3 (en) 1989-03-29
DE3886237D1 (de) 1994-01-27
EP0280578A2 (de) 1988-08-31
ATE98649T1 (de) 1994-01-15
ES2061638T3 (es) 1994-12-16
JPS63276494A (ja) 1988-11-14
EP0280578B1 (de) 1993-12-15

Similar Documents

Publication Publication Date Title
DE3886237T2 (de) Reinigung von LFA-3.
EP0391526A3 (de) Reinigungsverfahren für Antikörper
BR9002017A (pt) Acido 2-0-.-d-glicopiranosil-i-ascorbico cristalino,processo de sua preparacao,e seus usos
FR2603581B1 (fr) Procede pour isoler et purifier des aminoacides par chromatographie
BR8701791A (pt) Processo para separacao de monoxido de carbono tendo pureza substancialmente constante
GB8728326D0 (en) Separation & purification of cyclodextrins
NZ218700A (en) Process for purification of paraffinic hydrocarbons containing mercaptan impurities
FR2552675B1 (fr) Procede de separation et de purification d'elements metalliques par chromatographie a deplacement
DE3583043D1 (de) Verfahren zur reinigung von podophyllotoxin.
KR890700609A (ko) 정제된 혈소판으로 부터 유도한 성장 인자 및 그의 정제방법
ES2105033T3 (es) Metodo de purificacion de proteinas.
FI103974B1 (fi) Menetelmä proteiinin puhdistamiseksi
EP0603671A3 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen.
DK443586D0 (da) Vandrensningsproces
ES2041690T3 (es) Metodo para la purificacion de anticuerpos.
DK0383645T3 (da) Fremgangsmåde til fremstilling af antihæmofilifaktor (FVIIIc) med meget høj renhed
FR2602772B1 (fr) Procede de purification de l'acetate de tocopherol
AU571713B2 (en) Method of purification of lpf-ha from bordetella pertussis
FR2559153B1 (fr) Procede de purification d'oxacephalosporines
RO92831A2 (ro) Procedeu de purificare a polietilenglicolilor
NO175145C (no) Fremgangsmåte for rensing av 2,2',4,4',6,6'-hexnanitrostilben(HNS)
EP0316964A3 (en) Process for the purification of podophyllotoxin
DE68918436D1 (de) Adsorptives Trennungsverfahren zur Reinigung von 2,6-Dimethylnaphthalin.
MY102245A (en) Purification of antibodies
RO91391A2 (ro) Procedeu de purificare a 3,4-dimetil-5-sulfanilamidoizoxazolului

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee